Please login to the form below

Not currently logged in
Email:
Password:

Johnson & Johnson buys $1bn Elan stake

J&J will invest $1bn (£600m) in Elan and commit $500m to help fund development of the company's late-stage products for Alzheimer's

Johnson & Johnson(J&J) will invest $1bn (£600m) in the Irish-American company Elan and commit an additional $500m to help fund development of the company's late-stage products for Alzheimer's disease.

In return, the US healthcare products group will acquire an 18.4 per cent stake in the company and assume majority control of its two leading experimental Alzheimer's products, which are being developed in partnership with US giant Wyeth.

The deal ends months of uncertainty over Elan's financial stability and marks a vote of confidence in the development of a late-stage drug and vaccine for Alzheimer's which had been thrown into question by Pfizer's takeover of Wyeth.

Elan will hold a 49.9 per cent stake in the newly formed company. It will be entitled to a 49.9 per cent share of the profits and certain royalty payments if products developed under the Wyeth partnership reach market.  

Sheri McCoy, J&J worldwide chairman of pharmaceuticals said: "Alzheimer's disease is a significant unmet need in ageing populations globally. J&J's development capabilities, commercial experience and global reach will provide the foundation to accelerate the (Alzheimer's programme) and increase its potential for patients globally."

Shares in Elan have risen 40 per cent on the news. The deal is expected to close in the second half of the year.

6th July 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics